A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

Overview of attention for article published in BMC Cancer, January 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 247 followers.

A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer https://t.co/BUaL9YI6AT

04 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.